Author:
Chan Sarah,Brugha Rossa,Quyam Sadia,Moledina Shahin
Abstract
Pulmonary hypertension (PH) can develop in babies with bronchopulmonary dysplasia (BPD). PH is common in those with severe BPD and is associated with a high mortality rate. However, in babies surviving beyond 6 months, resolution of PH is likely. There is currently no standardised screening protocol for PH in BPD patients. Diagnosis in this group relies heavily on transthoracic echocardiography. Management of BPD-PH should be led by a multidisciplinary team and focus on optimal medical management of the BPD and associated conditions that may contribute to PH. PH-targeted pharmacotherapies have been used in BPD-PH. To date, these have not been investigated in clinical trials and evidence of their efficacy and safety is absent.Educational aimsTo identify those BPD patients most at risk of developing PH.To be aware of detection, multidisciplinary management, pharmacological treatment and monitoring strategies for BPD-PH patients.To understand the potential clinical course for patients with BPD-PH and that evidence on efficacy and safety of PH-targeted pharmacotherapy in BPD-PH is limited.
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference41 articles.
1. World Health Organization . Preterm birth: key facts. Date last accessed: 7 August 2022. Date last updated: 14 November 2022. www.who.int/news-room/fact-sheets/detail/preterm-birth
2. Royal College of Paediatrics and Child Health (RCPCH) . National Neonatal Audit Programme (NNAP) 2020 Annual Report on 2019 Data. London, RCPCH, 2020. www.rcpch.ac.uk/work-we-do/clinical-audits/nnap
3. Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States
4. European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia
5. Bronchopulmonary Dysplasia
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献